Covidien buys PAD device maker

Editorial Staff | | Cardiovascular Business | Vascular & Endovascular

Covidien has signed a definitive agreement to acquire CV Ingenuity, a company that provides technologies to relieve vascular obstructions, inhibit restenosis and allow natural vessel healing in patients with peripheral arterial disease (PAD).

The companies expect to complete the acquisition in the first calendar quarter of 2013. Financial terms of the transaction were not disclosed.

The Fremont, Calif.-based CV Ingenuity said its core technology, while still in the investigational phase, is a drug-coated balloon (DCB) platform with a proprietary, rapid-release system.

As a result of this transaction, Covidien said it expects to increase research and development expenditures for the next several years to fund the clinical development of CV Ingenuity technologies. Additional expenditures are expected to be more than $20 million in the second half of fiscal 2013 and more than $30 million in fiscal 2014. Despite these additional expenditures and the negative impact on selling, general and administrative expenses from the transaction, Covidien is reaffirming all of its prior guidance ranges, which were last updated on Nov. 9. Also, Covidien does not anticipate receiving FDA approval for a DCB product using the CV Ingenuity technology until fiscal 2017.

Once the transaction has been completed, Covidien will report the CV Ingenuity business as part of its vascular product line in the medical devices segment.

Editorial Staff

Related Content

IVUS-guided PCI reduces risks in patients with diabetes
LAAC with Watchman FLX reduces bleeding risks after AFib ablation
Bioresorbable BTK stent superior to ballon angioplasty at 2 years
Shockwave Medical’s IVL technology delivers more positive outcomes for PAD patients
Standing desks fail to lower blood pressure or minimize heart risks—they may even do damage
IVL vs. RA for chronic total occlusion PCI: Key data cardiologists should know

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."